Literature DB >> 25491905

Ulcerative colitis-associated pulmonary nodules with cavity formation successfully treated with mesalazine and granulocyte-monocyte apheresis.

Hiroaki Nomoto1, Yoshikazu Hayashi, Satoshi Shinozaki, Tomonori Yano, Keijiro Sunada, Wataru Sasao, Aya Kitamura, Mai Ohashi, Shuhei Hiyama, Alan Kawarai Lefor, Hironori Yamamoto.   

Abstract

Pulmonary complications of ulcerative colitis (UC) are relatively rare. Generally, pulmonary lesions with cavity formation are difficult to distinguish from infections or Wegener's granulomatosis lesions. A 15-year-old female with no remarkable past medical history had multiple pulmonary nodules on chest X-ray. Since empirical treatment with wide-spectrum antibiotics did not improve her symptoms, she was transferred for further evaluation. Chest radiography and computed tomography (CT) scan showed multiple bilateral pulmonary nodules with cavity formation, 8-65 mm in diameter, located mainly in the right lung. She was diagnosed with UC based on sigmoidoscopy. She was treated with mesalazine and granulocyte-monocyte apheresis (GMA). Steroids were not administered, because an infectious disease could not be excluded. Seven days after starting GMA, her symptoms and laboratory findings improved, and she was discharged. After the completion of 10 courses of GMA, chest radiography and CT scan showed marked diminution of the pulmonary lesions. UC-associated pulmonary lesions can be treated without steroid administration, and we suggest that this strategy is an option for a patient with UC-associated pulmonary lesions that cannot be differentiated from an infection.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25491905     DOI: 10.1007/s12328-014-0530-2

Source DB:  PubMed          Journal:  Clin J Gastroenterol        ISSN: 1865-7265


  9 in total

1.  Sulfasalazine pulmonary toxicity in ulcerative colitis mimicking clinical features of Wegener's granulomatosis.

Authors:  S M Salerno; E J Ormseth; B J Roth; C A Meyer; E D Christensen; T A Dillard
Journal:  Chest       Date:  1996-08       Impact factor: 9.410

2.  Pulmonary complications resembling Wegener's granulomatosis in ulcerative colitis with elevated proteinase-3 anti-neutrophil cytoplasmic antibody.

Authors:  Akiyoshi Kasuga; Yasushi Mandai; Tatsuro Katsuno; Toru Sato; Taketo Yamaguchi; Osamu Yokosuka
Journal:  Intern Med       Date:  2008-07-01       Impact factor: 1.271

Review 3.  Relationship of extraintestinal involvements in inflammatory bowel disease: new insights into autoimmune pathogenesis.

Authors:  K M Das
Journal:  Dig Dis Sci       Date:  1999-01       Impact factor: 3.199

Review 4.  A limited form of Wegener's granulomatosis with bronchiolitis obliterans organizing pneumonitis-like variant in an ulcerative colitis patient.

Authors:  Shuichi Yano; Kanako Kobayashi; Kazuhiro Kato; Kengo Nishimura
Journal:  Intern Med       Date:  2002-11       Impact factor: 1.271

5.  Unusual pulmonary complication of ulcerative colitis with a rapid response to corticosteroids: case report.

Authors:  G A Hilling; D A Robertson; A H Chalmers; H S Rigby
Journal:  Gut       Date:  1994-06       Impact factor: 23.059

6.  Pulmonary manifestations of ulcerative colitis mimicking Wegener's granulomatosis.

Authors:  J Stebbing; F Askin; E Fishman; J Stone
Journal:  J Rheumatol       Date:  1999-07       Impact factor: 4.666

7.  Pulmonary involvement in inflammatory bowel disease.

Authors:  Aydin Yilmaz; Nilgün Yilmaz Demirci; Derya Hoşgün; Enver Uner; Yurdanur Erdoğan; Atila Gökçek; Atalay Cağlar
Journal:  World J Gastroenterol       Date:  2010-10-21       Impact factor: 5.742

8.  Increased frequency of bronchial hyperresponsiveness in patients with inflammatory bowel disease.

Authors:  E Louis; R Louis; V Drion; V Bonnet; A Lamproye; M Radermecker; J Belaiche
Journal:  Allergy       Date:  1995-09       Impact factor: 13.146

Review 9.  The lung in inflammatory bowel disease.

Authors:  P Camus; F Piard; T Ashcroft; A A Gal; T V Colby
Journal:  Medicine (Baltimore)       Date:  1993-05       Impact factor: 1.889

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.